Menu Search
Equities

EDAG Engineering Group AG

ED4:MUN

EDAG Engineering Group AG

Actions
  • Price (EUR)11.80
  • Today's Change0.05 / 0.43%
  • Shares traded-1.00
  • 1 Year change+9.26%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 07:01 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates of portfolio a various self-care brands focusing primarily on dermatological solutions, through its subsidiaries. Products within the portfolio include neuromodulators, fillers, and biostimulators. These products are designed to relax wrinkles via injects, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, from research and development to manufacturing. In addition, other value adding platforms, including education, scientific engagements, and other services are offered.

  • Revenue in EUR (TTM)851.31m
  • Net income in EUR27.60m
  • Incorporated2015
  • Employees9.06k
  • Location
    EDAG Engineering Group AGSchlossgasse 2ARBON 9320SwitzerlandCHE
  • Phone+41 715443311
  • Fax+41 715443310
  • Websitehttps://www.edag.com/de
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.